Alembic Pharma's cholesterol drug gets US FDA nod
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Alembic Pharmaceuticals has received approval from the US health regulator for its abbreviated new drug application (ANDA) for its Fenofibric Acid Delayed-Release Capsules, 45mg and 135mg,

The approved product is therapeutically equivalent to the reference listed drug product Trilipix Delayed-Release capsules of Abbvie Inc. Fenofibric Acid Delayed-Release capsules are indicated as an adjunctive therapy to diet to reduce triglyceride (TG) in patients with hypertriglyceridemia and reduce elevated LDL-C, total cholesterol, and increase high-density lipoprotein (HDL) (good) cholesterol levels.

http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharmas-cholesterol-drug-gets-us-fda-nod/articleshow/58680103.cms
Preview
Like
Comment
Share